BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 108.21. In the previous year, Cash Conversion Cycle (CCC) was 159.33 — a change of -32.08% (lower).

Cash Conversion Cycle

108.21

YoY

-32.08%

Last updated:

Cash Conversion Cycle (CCC) of BrightGene Bio-Medical Technology Co is 2025 108.21 . Cash Conversion Cycle (CCC) of BrightGene Bio-Medical Technology Co was 2024 159.33 . It decreases by -32.08% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
254.66 CNY
Jan 1, 2019
303.09 CNY
Jan 1, 2020
209.82 CNY
Jan 1, 2021
120.11 CNY
Jan 1, 2022
135.96 CNY
Jan 1, 2023
169.08 CNY
Jan 1, 2024
159.33 CNY
Jan 1, 2025
108.21 CNY
The BrightGene Bio-Medical Technology Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
108.21-32.08%
159.33-5.77%
169.08+24.36%
135.96+13.19%
120.11-42.75%
209.82-30.77%
303.09+19.02%
254.66+4.40%
243.92+4.31%
233.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Cash Conversion Cycle (CCC) of BrightGene Bio-Medical Technology Co is 108.21 in 2025.

Cash Conversion Cycle (CCC) of BrightGene Bio-Medical Technology Co changed from 159.33 to 108.21, representing a -32.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co